ZTS
Zoetis Inc.Evidence as of 2026-10-07The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on ZTS
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
Overview · Zoetis Inc.
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectiv…
Management team
- Mr. Nick Ashton · Executive VP and President of Global Manufacturing & SupplyFind on LinkedIn
- Ms. Jeannette Ferran Astorga · Executive VP of Corporate Affairs & Communications and Chief Sustainability OfficerFind on LinkedIn
- Dr. Robert J. Polzer Ph.D. · Executive VP and President of Research & DevelopmentFind on LinkedIn
- Mr. Steven Frank · Vice President of Investor RelationsFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it, not a rating or a recommendation.
−0.2 on a −2 to +2 scale (was −0.3 before the debate changed the read).
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled. The rest of the page is the evidence behind it.
The evidence balance is Mixed ( -0.2 of a possible +2; confidence high). Revenues reported were $2,400,000,000 in Q3 2025 (fiscal quarter ended 2025-10-31), $2,262,000,000 in Q1 2026 (fiscal quarter ended 2026-05-01), and $2,468,000,000 in Q2 2026 (fiscal quarter ended 2026-07-31). Diluted EPS were $ 1.63, $ 1.42 and $ 1.65 in those same quarters, respectively.
Share count declined from 443,183,472 as of 2025-08-01 to 413,223,602 as of 2026-07-31. Long-term noncurrent debt rose from $ 7,069,000,000 as of 2025-09-30 to about $ 9,045,000,000 at subsequent quarter ends through 2026-06-30, while cash and cash equivalents fell from $ 2,084,000,000 to $ 1,476,000,000 over the same span and stockholders' equity declined from $ 5,398,000,000 to $ 3,148,000,000. Market signals show the three‑year maximum drawdown at -64.2% and a drawdown from the three‑year high of -63.0% as of 2026-10-06, price sitting 3.9% below the 50‑day simple moving average and 26.9% below the 200‑day simple moving average, weak momentum metrics (momentum_6m -38.7%, momentum_12_1 -49.9%), and dividend yield and growth that rank comparatively favorably in the research universe.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else (no outside knowledge, no browsing), so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC (revenue, margins, income, debt and share count, quarter by quarter) and reports which way the trend is running.
Revenues were $2,400,000,000 in fiscal Q3 2025 (2025-07-01 to 2025-09-30, 3mo), $2,262,000,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo) and $2,468,000,000 in fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo).
XBRL companyfacts · 0001555280-25-000274Diluted earnings per share were $1.63 in fiscal Q3 2025 (2025-07-01 to 2025-09-30, 3mo), $1.42 in fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo) and $1.65 in fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo).
XBRL companyfacts · 0001555280-25-000274Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full: its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet; its risk analysis fills in once that lands.
Zoetis filed its annual report on Form 10-K on February 12, 2026, which includes expanded risk-factor disclosures that newly call out risks related to AI use and IP ownership, ERP system transition risks, PFAS chemical regulation, and exposures tied to convertible senior notes and conditional conversion features.
10-K filed 2026-02-12The earlier annual report on Form 10-K filed February 13, 2025, removed or replaced a number of prior risk phrasings that had described similar operational, trade policy and data-privacy risks, indicating a material redrafting of the risk-factor section between the 2025 and 2026 10-Ks.
10-K filed 2025-02-13Reads the signal panel above (momentum, volatility, drawdown, relative strength and beta) and ranks each against the whole research universe rather than judging it in isolation.
As of 2026-10-06, the three-year maximum drawdown is -64.2% and the drawdown from the three-year high is -63.0%, with the three-year drawdown ranked in the 7th percentile of the 815-stock research universe.
Moneyta signal set · 2026-10-06As of 2026-10-06, short- and medium-term momentum are weak: momentum_6m is -38.7% and momentum_3m is -4.4%, and the six-month momentum rank is in the 3th percentile of the 815-stock research universe.
Moneyta signal set · 2026-10-06weakened in debateReads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
Institutional 13F-reported holdings total "$28.37B" as of 2026-06-30; the report shows 1,441 holders, a quarter-over-quarter holder count decline of 182, a quarter-over-quarter value change of -39.9%, and 352 exited positions.
13F holdings · 1441 filers · as of 2026-06-30Largest reported institutional holders on the 13F are BlackRock, Inc. ($2.83B), VANGUARD CAPITAL MANAGEMENT LLC ($1.87B), VANGUARD PORTFOLIO MANAGEMENT LLC ($1.71B), STATE STREET CORP ($1.41B), and STATE FARM MUTUAL AUTOMOBILE INSURANCE CO ($1.14B) as of 2026-06-30.
13F holdings · 1441 filers · as of 2026-06-30Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Coverage includes a full earnings call transcript for Zoetis' Q2 2026 results, indicating company-specific reporting on its quarterly performance.
News · benzinga.com · 2026-10-06An article reports an executive disclosure of RSU vesting and stock transactions by Zoetis EVP Julie Fuller on September 30, 2026, a company-specific insider activity item.
News · kalkinemedia.com · 2026-10-02Reads parsed Forms 3/4/5: who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
Frank A. Damelio, a director, reported an open-market purchase of 6,650 shares for "$501k" on 2026-05-13.
Form 4 · DAMELIO FRANK A (Director) · $501k bought · 2026-05-13Michael B. McCallister, a director, reported an open-market purchase of 3,000 shares for "$233k" on 2026-05-11.
Form 4 · MCCALLISTER MICHAEL B (Director) · $233k bought · 2026-05-11Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model calculates the market-implied free cash flow (FCF) growth rate that today's price would justify as 10.36%.
Valuation inputs · SEC XBRL + stored EOD closePrice-to-trailing-twelve-month FCF is 21.15 and FCF per share is $3.3732 (FCF ttm = $1.409 billion, shares used ~417.7 million diluted wavg).
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score. The argument is shown, not hidden, so you can judge the reasoning yourself.
Several company-level signals in the evidence jointly support a favorable read. Reported quarterly revenues and a rebound in diluted EPS in fiscal Q2 2026 show recurring operating performance (fundamentals-0, fundamentals-1), while a steady reduction in shares outstanding points to material share-count reduction (fundamentals-2) that can increase per-share economics. Multiple open-market insider purchases in May 2026 (insider-0, insider-1, insider-2), sizable institutional ownership by major asset managers (ownership-1), and inclusion in broad/sector ETFs (ownership-2) indicate continued institutional and insider engagement. Valuation and cash-flow metrics show a relatively low P/E (valuation-2) with meaningful trailing FCF and OCF (valuation-1, valuation-4) and material non-cash DDA add-backs (valuation-5), which together strengthen the case that operating cash generation underpins payouts and capital allocation choices. These points address several market-focused negatives: while the security shows a large multi-year drawdown and weak momentum (market-0, market-1, market-2), the company's operating cash flow, dividend profile (market-4), and low market sensitivity (market-5) are evidence strengths that temper purely price-based concerns.
Chair's verdict, claim by claim
Fragility · computed, not argued
diversified0.27
38 surviving claims rest on 22 distinct sources; the heaviest analyst carries 18% of them, and 97% of what the desk raised survived the debate.
The reading rests on a moderate breadth of sources but a relatively small group of analysts contributed a disproportionate share of surviving claims; that increases sensitivity to individual analyst errors or biases. High survival through internal debate suggests internal consistency, but source concentration and an 18% heaviest-analyst share mean this read should be treated as informative yet somewhat fragile — corroboration from additional independent sources would strengthen confidence.
Peer context · computed, not argued
12-1 momentum ranks 3rd of 3 in Drug Manufacturers—Specialty & Generic (as of 2026-10-06).
6-month relative strength ranks 3rd of 3 in Drug Manufacturers—Specialty & Generic (as of 2026-10-06).
90-day volatility ranks 2nd of 3 in Drug Manufacturers—Specialty & Generic (as of 2026-10-06).
dividend yield ranks 1st of 3 in Drug Manufacturers—Specialty & Generic (as of 2026-10-06).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment. When the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here (no outside knowledge, no browsing), and each card shows who read it and what it contributed to the score.
11 filings· 3 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data, not retyped or estimated.
Read by Mercer+0.0 to the score
13 documents· 3 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes+0.2 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash−0.5 to the score
3 holdings records· 1 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.3 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
8 filings· 2 cited
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state, with stated and inferred flags kept apart.
Read by Talbot+0.8 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only; it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal; the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
The full terminal on ZTS Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Get this for the names you actually hold
Every name in your portfolio, researched the same way, plus the one thing no sample can show: how each one sits inside what you already own.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.